Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.43 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.33 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.33 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.33 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6445741 | 0.89 | EPHX1 (0.46) | CA1CA12CA14CA7CA2 | |
| SCHEMBL24247669 | 0.85 | EPHX1 (0.51) | EPHX1 | |
| SCHEMBL6460339 | 0.83 | EPHX1 (0.38) | CA1CA2EPHX1LMNA | |
| SCHEMBL28489251 | 0.82 | EPHX1 (0.37) | CA1CA2EPHX1 | |
| SCHEMBL28489693 | 0.82 | EPHX1 (0.37) | CA1CA2EPHX1 | |
| SCHEMBL28497015 | 0.82 | EPHX1 (0.37) | CA1CA2EPHX1 | |
| Butane SCHEMBL30418608 | 0.75 | EPHX1 (0.50) | CA1CA7CA2EPHX1 | |
| Butane SCHEMBL29598328 | 0.75 | EPHX1 (0.50) | CA1CA7CA2EPHX1 | |
| SCHEMBL22821168 | 0.75 | EPHX1 (0.38) | CA1CA2EPHX1 | |
| SCHEMBL28488919 | 0.73 | EPHX1 (0.37) | CA1CA2EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050074668-A1 | Perfluorinated amide salts and their uses as ionic conducting materials | MICHOT CHRISTOPHE (FR) | 2005-04-07 | — | — | US | disclosed |
| US-20030052310-A1 | Perfluorinated amide salts and their uses as ionic conducting materials | MICHOT CHRISTOPHE (FR) | 2003-03-20 | — | — | US | disclosed |
| EP-0850920-B1 | Ionic conductive materials comprising salts of perfluorinated amides and uses thereof | CENTRE NAT RECH SCIENT (FR) | 2002-09-11 | — | — | EP | disclosed |
| US-20020009650-A1 | Perfluorinated amide salts and their uses as ionic conducting materials | MICHOT CHRISTOPHE (FR) | 2002-01-24 | — | — | US | disclosed |
| US-6319428-B1 | Perfluorinated amide salts and their uses as ionic conducting materials | HYDRO-QUEBEC (CA) | 2001-11-20 | — | — | US | disclosed |
| WO-1998029388-A1 | PERFLUORINATED AMIDE SALTS AND THEIR USES AS IONIC CONDUCTING MATERIALS | HYDRO-QUEBEC (CA) | 1998-07-09 | — | — | WO | disclosed |
| EP-0850920-A2 | Salts of perfluorinated amides and their uses as ionic conductive materials | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 1998-07-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020009650-A1 | Perfluorinated amide salts and their uses as ionic conducting materials | AFF4, NHERF1, AFF2 | CA1 860/4885CA12 1237/4885CA14 845/4885 |
| US-20050074668-A1 | Perfluorinated amide salts and their uses as ionic conducting materials | AFF4, AFF2, AFF1 | CA1 689/4885CA12 987/4885CA14 1065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.